儿童霍奇金淋巴瘤诱导化疗后骨骼(骨髓和骨)受累的18F-FDG PET反应:是否需要特定的反应标准?
该研究基于EuroNet-PHL-C1试验中1068例儿童霍奇金淋巴瘤患者的基线PET扫描,由中心审查评估骨骼受累情况,区分PET-only病灶、骨髓病灶和骨病灶。2周期化疗后(PET-2),骨骼受累的完全代谢缓解率为73%(101/139),淋巴结为68%(94/139);初始qPET和MTV较高的骨骼病灶PET-2反应更差。结论认为现行骨骼PET反应标准(与局部骨骼背景比较)适用,骨闪烁现象似乎无关。
要点
- 139/1068例(13%)儿童霍奇金淋巴瘤患者存在骨骼受累,其中PET-only 44例、骨髓32例、骨63例。
- PET-2时骨骼完全代谢缓解率为73%(101/139),淋巴结为68%(94/139)。
- PET-only病灶PET-2转阴率最高(42/44,95%),骨髓病灶69%(22/32),骨病灶59%(37/63)。
核心结论
- 在儿童霍奇金淋巴瘤患者中,PET-2时骨骼受累的完全缓解率与淋巴结受累相似。
- 骨闪烁现象似乎无关。
- 总体而言,现行骨骼PET反应标准(与局部骨骼背景比较)是适用的。
- 骨骼病灶的初始qPET和MTV可预测PET-2结果,两者数值越高与PET-2反应越差相关。
研究设计与样本
- 对EuroNet-PHL-C1试验中1068例儿童霍奇金淋巴瘤患者的基线PET扫描进行中心审查,评估骨骼受累情况。
- 区分三种骨骼病灶类型:PET-only病灶、骨髓病灶(经MRI或骨髓活检确认)和骨病灶。
- 计算每个骨骼病灶的qPET和MTV,并评估所有PET-2扫描的残留肿瘤活性。
- 比较骨骼受累与淋巴结受累在PET-2时的完全代谢缓解率。
主要发现
- 1068例患者中139例(13%)存在骨骼受累,包括PET-only 44例、骨髓32例、骨63例。
- 139例骨骼受累患者中,101例(73%)在PET-2时骨骼转为阴性,94例(68%)淋巴结转为阴性。
- PET-2骨骼转阴率:PET-only患者42/44(95%),骨髓患者22/32(69%),骨患者37/63(59%)。
- 转为PET-2阴性的病灶初始中位qPET为2.74、MTV为2 cm³,持续阳性病灶分别为3.84和7 cm³。
关键数值与推荐
- 骨骼受累定义为基线PET显示骨骼病灶,分为PET-only、骨髓(经MRI或骨髓活检确认)和骨病灶三类。
- PET-2反应评估采用现行骨骼PET反应标准,即与局部骨骼背景比较。
- 初始qPET和MTV用于分析对PET-2反应的影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To determine whether the current 18F-FDG PET response criterion for skeletal involvement in Hodgkin lymphoma (HL) is suitable, we performed a systematic evaluation of the different types of skeletal involvement and their response on PET after 2 cycles of chemotherapy (PET-2). A secondary objective was to observe the influence of the initial uptake intensity (measured as qPET) and initial metabolic tumor volume (MTV) of skeletal lesions on the PET-2 response. Methods: The initial PET scans of 1,068 pediatric HL patients from the EuroNet-PHL-C1 trial were evaluated for skeletal involvement by central review. Three types of skeletal lesions were distinguished: PET-only lesions (those detected on PET only), bone marrow (BM) lesions (as confirmed by MRI or BM biopsy), and bone lesions. qPET and MTV were calculated for each skeletal lesion. All PET-2 scans were assessed for residual tumor activity. The rates of complete metabolic response for skeletal and nodal involvement on PET-2 were compared. Results: Of the 1,068 patients, 139 (13%) showed skeletal involvement (44 PET-only, 32 BM, and 63 bone). Of the 139 patients with skeletal involvement, 101 (73%) became PET-2-negative in the skeleton and 94 (68%) became PET-2-negative in the lymph nodes. The highest number of PET-2-negative scans in the skeleton was 42 (95%) in the 44 PET-only patients, followed by 22 skeletal lesions (69%) in the 32 BM patients and 37 (59%) in the 63 bone patients. Lesions that became PET-2-negative showed a lower initial median qPET (2.74) and MTV (2 cm3) than lesions that remained PET-2-positive (3.84 and 7 cm3, respectively). Conclusion: In this study with pediatric HL patients, the complete response rate for skeletal involvement on PET-2 was similar to that for nodal involvement. Bone flare seemed to be irrelevant. Overall, the current skeletal PET response criterion-comparison with the local skeletal background-is well suited. The initial qPET and MTV of skeletal lesions were predictive of the PET-2 result. Higher values for both parameters were associated with a worse PET-2 response.
引用
- Georgi TW, Kluge R, Kurch L, et al. 18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required? J Nucl Med. 2018. PMID: 29653979. doi:10.2967/jnumed.117.205633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。